1063 patents
Page 9 of 54
Utility
C3-SUBSTITUTED 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
27 Apr 23
Christine M. TARBY, Qiang CONG, Ashvinikumar V. GAVAI, Sanjeev GANGWAR, Matthias BROEKEMA, Patrice GILL, Prasanna SIVAPRAKASAM, Walter L. JOHNSON, Murugaiah Andappan Murugaiah SUBBAIAH, Yam B. POUDEL
Filed: 26 Jan 21
Utility
1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
27 Apr 23
Qian ZHANG, Sanjeev GANGWAR, Ashvinikumar V. GAVAI, Qiang CONG, Yam B. POUDEL, Liqi HE, Prasanna SIVAPRAKASAM, Christine M. TARBY
Filed: 26 Jan 21
Utility
1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
27 Apr 23
Christine M. TARBY, Matthias BROEKEMA, Ashvinikumar V. GAVAI, Sanjeev GANGWAR, Naidu S. CHOWDARI, Walter L JOHNSON, Murugaiah ANDAPPAN MURUGAIAH SUBBAIAH
Filed: 26 Jan 21
Utility
Sphingosine 1 Phosphate Receptor Modulators
27 Apr 23
Roger BAKALE, Jeff SCHKERYANTZ, Maurice MARSINI
Filed: 25 Mar 21
Utility
Histone Demethylase Inhibitors
20 Apr 23
The present invention relates generally to compositions and methods for treating cancer and neoplastic disease.
Amogh Boloor, Toufike Kanouni, Jeffrey Alan Stafford, James Marvin Veal, Michael Brennan Wallace
Filed: 3 Nov 22
Utility
Substituted Pyrazole Compounds As Toll Receptor Inhibitors
20 Apr 23
Laxman Pasunoori, Sreekantha Ratna Kumar, Pitani Veera Venkata Srinivas, Vikram Bhogadi, Duraisamy Kunchithapatham Srinivasan, Anupama Kandhi Ramachandra Reddy, Rushith Kumar Anumula, Alaric J. Dyckman
Filed: 30 Oct 20
Utility
1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
20 Apr 23
Yam B. POUDEL, Matthew COX, Liqi HE, Daniel O'MALLEY, Ashvinikumar V. GAVAI, Sanjeev GANGWAR, Matthias BROEKEMA, Prasanna SIVAPRAKASAM, Christine M. TARBY, Murugaiah ANDAPPAN MURUGAIAH SUBBAIAH,Murugaiah
Filed: 26 Jan 21
Utility
Substituted Nitrogen Containing Compounds
20 Apr 23
Navnath Dnyanoba Yadav, Rajeev S. Bhide, Rajesh Onkardas Bora, Prashantha Gunaga, Manoranjan Panda, Eldon Scott Priestley, Jeremy Richter
Filed: 5 Oct 22
Utility
Substituted Piperazine Derivatives Useful As T Cell Activators
20 Apr 23
Upender Velaparthi, Chetan Padmakar Darne, Richard E. Olson, Jayakumar Sankara Warrier
Filed: 22 Dec 20
Utility
1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
20 Apr 23
Heng CHENG, Christine M. TARBY, Sanjeev GANGWAR, Ashvinikumar V. GAVAI, Walter L. JOHNSON, Yam B. POUDEL, Prasanna SIVAPRAKASAM, Patrice GILL, Andrew F. DONNELL, Murugaiah Andappan Murugaiah SUBBAIAH
Filed: 26 Jan 21
Utility
PYRAZINO[2,3-b]PYRAZINE mTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAY
20 Apr 23
Jan ELSNER, Kimberly E. Fultz, Roy L. HARRIS, III, Branden Gingsee LEE, Loui Thomas Madakamutil, Deborah S. Mortensen, Rama Krishna Narla, Garrick K. PACKARD, Patrick PAPA, Jason PARNES, Sophie Perrin-Ninkovic, Jennifer RIGGS, Sabita SANKAR, John J. Sapienza, Graziella I. Shevlin, Lida Tehrani, Weiming XU, Jingjing ZHAO
Filed: 25 Feb 22
Utility
ANTI-CCR8 Antibodies for Treating Cancer
20 Apr 23
This disclosure provides isolated antibodies, for example, monoclonal antibodies, that specifically bind to the C-C Motif Chemokine Receptor 8 (CCR8) expressed on the surface of a cell and mediate depletion of the CCR8-expressing cell by anti-body-dependent cellular cytotoxicity (ADCC).
Ruth Yin-Zong Lan, Olufemi A. Adelakun, Ishita Barman, Joseph Campbell, SJ Jian Zhe Diong, Felix Findeisen, Danielle M. Greenawalt, Renu Jain, Amy D. Jhatakia, John K. Lee, Peter S.K. Lee, Linda Liang, Kai Lu, Bryan McDonald, Paul Mesko, Arvind Rajpal, Sharmila Sambanthamoorthy, Mark J. Selby, Nathan O. Siemers, Pavel Strop, Gaby A. Terracina, Xi-Tao Wang
Filed: 22 Mar 21
Utility
Antibody screening methods
18 Apr 23
Provided are methods and compositions for the production of novel antibodies that bind specifically to a target antigen.
Yan Chen, Tod M. Woolf, Richard W. Wagner
Filed: 30 Apr 20
Utility
Forms and compositions of a MK2 inhibitor
18 Apr 23
The present invention provides solid forms of an MK2 inhibitor, compositions thereof, and methods of using the same.
Jianxin Han, Lianfeng Huang, Uday Jain, Ying Li, John Malona, Kevin Molter, Chittari Pabba, Alexander L. Ruchelman, Jean Xu, Daozhong Zou
Filed: 29 Dec 20
Utility
Compositions Comprising a Combination of an ANTI-LAG-3 Antibody, a PD-1 Pathway Inhibitor, and an Immunotherapeutic Agent
13 Apr 23
Provided are methods for clinical treatment of malignant tumors (e.g., advanced solid tumors) using a combination of an anti-LAG-3 antibody, an anti-PD-1 antibody, and an immunotherapeutic agent.
Alan J. KORMAN, Nils LONBERG, Mark J. SELBY, Jeffrey JACKSON
Filed: 10 Aug 22
Utility
Substituted Diaminocarboxamide and Diaminocarbonitrile Pyrimidines, Compositions Thereof, and Methods of Treatment Therewith
13 Apr 23
Brydon L. Bennett, Mercedes Delgado, Jan Elsner, Paul Erdman, Robert Hilgraf, Laurie Ann LeBrun, Meg McCarrick, Mehran F. Moghaddam, Mark A. Nagy, Stephen Norris, David A. Paisner, William J. Romanow, Yoshitaka Satoh, Marianne Sloss, Jayashree Tikhe, Won Hyung Yoon
Filed: 29 Mar 22
Utility
Tricyclic Heteroaryl Compounds Useful As IRAK4 Inhibitors
13 Apr 23
Saleem Ahmad, Lidet A. Negash
Filed: 2 Feb 21
Utility
Indole carboxamide compounds
11 Apr 23
Qingjie Liu, Scott Hunter Watterson, John E. Macor, Khehyong Ngu, Saleem Ahmad
Filed: 3 Dec 20
Utility
Methods and compositions for deuterated biologics
11 Apr 23
Deuterated polymer-biomolecule conjugates and the synthesis and use of deuterated polymer-biomolecule conjugates for detecting the location of specific molecules, e.g., cell surface molecules, in a subject, and for imaging various processes within the body, for detecting the location of molecules associated with disease pathology, and for monitoring disease progression are disclosed.
Michael J. Smith, Haiying Tang, Paul E. Morin, Harold J. Malone, Luciano Mueller
Filed: 10 Nov 20
Utility
Prodruggable antibodies, prodrugs thereof, and methods of use and making
11 Apr 23
A prodrugged antibody has a blocking moiety attached to a Cys on its heavy or light chain via a linker having a cleavable moiety.
Stanley R. Krystek, Jr., Yong Zhang, Gregory D. Vite, Arvind Rajpal, Chetana Rao-Naik, Paul E. Morin, Mohan Srinivasan, Zheng Lin, Virginie Lafont, Alla Pritsker
Filed: 14 Aug 18